Advanced search

Cutaneous short-interfering RNA therapy

Barbara Geusens (UGent) , Niek Sanders (UGent) , Tarl Prow and Mireille Van Gele (UGent)
(2009) EXPERT OPINION ON DRUG DELIVERY. 6(12). p.1333-1349
Author
Organization
Abstract
Since the 1990s, RNA interference (RNAi) has become a major subject of interest, not only as a tool for biological research, but also, more importantly, as a therapeutic approach for gene-related diseases. The use of short-interfering RNAs (siRNAs) for the sequence-specific knockdown of disease-causing genes has led to numerous preclinical and even a few clinical studies. Applications for cutaneous delivery of therapeutic siRNA are now emerging owing to a strong demand for effective treatments of various cutaneous disorders. Although successful studies have been performed using several different delivery techniques, most of these techniques encounter limitations for translation to the clinic with regards to patient compliance. This review describes the principal findings and applications in cutaneous RNAi therapy and focuses on the promises and pitfalls of the delivery systems.
Keywords
cutaneous disorders, delivery techniques, siRNA, skin, MOUSE SKIN MODEL, GENE-TRANSFER, IN-VIVO, PENETRATION ENHANCERS, MALIGNANT-MELANOMA, DRUG CARRIERS, PLASMID DNA, ANTISENSE OLIGONUCLEOTIDES, TOPICAL APPLICATION, TRANSFECTION EFFICIENCY

Citation

Please use this url to cite or link to this publication:

Chicago
Geusens, Barbara, Niek Sanders, Tarl Prow, and Mireille Van Gele. 2009. “Cutaneous Short-interfering RNA Therapy.” Expert Opinion on Drug Delivery 6 (12): 1333–1349.
APA
Geusens, B., Sanders, N., Prow, T., & Van Gele, M. (2009). Cutaneous short-interfering RNA therapy. EXPERT OPINION ON DRUG DELIVERY, 6(12), 1333–1349.
Vancouver
1.
Geusens B, Sanders N, Prow T, Van Gele M. Cutaneous short-interfering RNA therapy. EXPERT OPINION ON DRUG DELIVERY. 2009;6(12):1333–49.
MLA
Geusens, Barbara, Niek Sanders, Tarl Prow, et al. “Cutaneous Short-interfering RNA Therapy.” EXPERT OPINION ON DRUG DELIVERY 6.12 (2009): 1333–1349. Print.
@article{771517,
  abstract     = {Since the 1990s, RNA interference (RNAi) has become a major subject of interest, not only as a tool for biological research, but also, more importantly, as a therapeutic approach for gene-related diseases. The use of short-interfering RNAs (siRNAs) for the sequence-specific knockdown of disease-causing genes has led to numerous preclinical and even a few clinical studies. Applications for cutaneous delivery of therapeutic siRNA are now emerging owing to a strong demand for effective treatments of various cutaneous disorders. Although successful studies have been performed using several different delivery techniques, most of these techniques encounter limitations for translation to the clinic with regards to patient compliance. This review describes the principal findings and applications in cutaneous RNAi therapy and focuses on the promises and pitfalls of the delivery systems.},
  author       = {Geusens, Barbara and Sanders, Niek and Prow, Tarl and Van Gele, Mireille},
  issn         = {1742-5247},
  journal      = {EXPERT OPINION ON DRUG DELIVERY},
  language     = {eng},
  number       = {12},
  pages        = {1333--1349},
  title        = {Cutaneous short-interfering RNA therapy},
  url          = {http://dx.doi.org/10.1517/17425240903304032},
  volume       = {6},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: